🚀 The Data is Decisive: Reshaping the Future of Lung Cancer Screening

This is big news. We are incredibly proud to have provided the digital infrastructure, AI capabilities, and recruitment engine behind the groundbreaking research just published in The Lancet. This isn't just a paper; it's the evidence that will directly shape the future of lung cancer screening.

💡The core question: How do we find the right people for life-saving low-dose CT screening?

• The Head-to-Head: The established categorical NELSON criteria vs. the advanced PLCOm2012 risk prediction model.

• The Key Finding: The PLCOm2012 model, using
an Age ≥1.58% six-year risk threshold, proved decisively more efficient AND more effective than NELSON criteria. This strengthens the case: Risk-model-based screening significantly improves early detection.

🎯The Engine Room: HANSE by the Numbers

These findings emerged directly from HANSE, a landmark study powered by Alcedis. When you integrate digital infrastructure, AI-assisted CT evaluation, and large-scale digital patient recruitment, the numbers speak:

- 400,000+ individuals approached.

- 13,000+ screened.

- 5,191 participants recruited in just 15 months.

🪅The Real-World Impact

This isn't academic. This work helped pave the way for a massive leap in public health: Germany's national lung cancer screening program, launching in 2026.

We are honored to continue supporting ongoing HANSE follow-up studies and advancing evidence-based, data-driven medicine in Germany and beyond.